scispace - formally typeset
R

Rakesh K. Jain

Researcher at Harvard University

Publications -  1528
Citations -  198912

Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.

Papers
More filters
Journal ArticleDOI

Angiogenesis in cancer and other diseases

Peter Carmeliet, +1 more
- 14 Sep 2000 - 
TL;DR: Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases and integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases, but owing to several unanswered questions, caution is needed.
Journal ArticleDOI

Photodynamic therapy for cancer

Dennis E. J. G. J. Dolmans, +2 more
- 01 May 2003 - 
TL;DR: PDT is being tested in the clinic for use in oncology — to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
Journal ArticleDOI

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Rakesh K. Jain
- 07 Jan 2005 - 
TL;DR: Emerging evidence supporting an alternative hypothesis is reviewed—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery.
Journal ArticleDOI

Molecular mechanisms and clinical applications of angiogenesis

Peter Carmeliet, +1 more
- 19 May 2011 - 
TL;DR: Preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
Journal ArticleDOI

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Mikhail Binnewies, +18 more
- 23 Apr 2018 - 
TL;DR: By parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient’s tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.